Summary
The primary objective of this study is to compare the progression-free survival (PFS) between
sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice
(TPC) and pembrolizumab in participants with previously untreated, locally advanced
inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell
death ligand 1 (PD-L1).